These compounds are not suitable for clinical use, but the ATX inhibitor GLPG1690 attenuated the progression of idiopathic pulmonary fibrosis in Phase 2 clinical trials [23,24]. The gene discussed is ENPP2; the disease is idiopathic pulmonary fibrosis.